Your browser doesn't support javascript.
loading
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial.
Chamie, Karim; Donin, Nicholas M; Klöpfer, Pia; Bevan, Paul; Fall, Barbara; Wilhelm, Olaf; Störkel, Stephan; Said, Jonathan; Gambla, Michael; Hawkins, Robert E; Jankilevich, Gustavo; Kapoor, Anil; Kopyltsov, Evgeny; Staehler, Michael; Taari, Kimmo; Wainstein, Alberto J A; Pantuck, Allan J; Belldegrun, Arie S.
Affiliation
  • Chamie K; Department of Urology, David Geffen School of Medicine at University of California, Los Angeles2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles3Institute of Urologic Oncology, David Geffen School of Medicine at University of California, L
  • Donin NM; Department of Urology, David Geffen School of Medicine at University of California, Los Angeles3Institute of Urologic Oncology, David Geffen School of Medicine at University of California, Los Angeles.
  • Klöpfer P; Wilex AG, Munich, Germany5MorphoSys AG, Munich, Germany.
  • Bevan P; Wilex AG, Munich, Germany.
  • Fall B; Wilex AG, Munich, Germany6Therawis Pharma GmbH, Munich, Germany.
  • Wilhelm O; Wilex AG, Munich, Germany6Therawis Pharma GmbH, Munich, Germany.
  • Störkel S; Institute of Pathology, University of Witten/Herdeke and Helios Hospital, Wuppertal, Germany.
  • Said J; Department of Pathology, David Geffen School of Medicine at University of California, Los Angeles.
  • Gambla M; Central Ohio Urology Group, Columbus.
  • Hawkins RE; Christie Hospital NHS Trust, University of Manchester, Manchester, England.
  • Jankilevich G; Clinical Oncology, Carlos G Durand Hospital, Buenos Aires, Argentina.
  • Kapoor A; Department of Clinical Oncology, McMaster University, Hamilton, Ontario, Canada.
  • Kopyltsov E; State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia.
  • Staehler M; Department of Urology, University Hospitals Munich, Campus Grosshadern, Munich, Germany.
  • Taari K; Department of Urology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Wainstein AJA; Faculty of Medical Sciences of Minas Gerais (FELUMA), Belo Horizonte, Brazil.
  • Pantuck AJ; Department of Urology, David Geffen School of Medicine at University of California, Los Angeles2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles3Institute of Urologic Oncology, David Geffen School of Medicine at University of California, L
  • Belldegrun AS; Department of Urology, David Geffen School of Medicine at University of California, Los Angeles2Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles3Institute of Urologic Oncology, David Geffen School of Medicine at University of California, L
JAMA Oncol ; 3(7): 913-920, 2017 Jul 01.
Article in En | MEDLINE | ID: mdl-27787547
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms / Antibodies, Monoclonal / Nephrectomy / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: JAMA Oncol Year: 2017 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms / Antibodies, Monoclonal / Nephrectomy / Antineoplastic Agents Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: JAMA Oncol Year: 2017 Document type: Article Country of publication: United States